About: First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia
Creator	Agar, Vivianne Aylwin, Mabel Donoso, Javiera Fierro, Margarita Iruretagoyena, Mirentxu Ibáñez, Sebastián Montes, José Poli, María Roessler, Patricia Roizen, Gigia Valenzuela, Omar
Source	MedRxiv
abstract	Introduction/objectives: An interleukin-6 inhibition strategy could be effective in selected COVID-19 patients. The objective is to present our experience of tocilizumab use in patients with severe COVID-19. Methods: Observational retrospective cohort study. Hospitalized patients were evaluated by our multidisciplinary team for eventual use of tocilizumab. Patients with progressive ventilatory impairment and evidence of a hyperinflammatory state despite usual treatment received tocilizumab 8 mg/kg intravenous (maximum dose 800 mg), in addition to standard treatment. The use and time of use of mechanical ventilation (MV), the change of the Alveolar-arterial (A-a) gradient, of the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) and of inflammation laboratory parameters after 72 hours of tocilizumab use was evaluated. Results: 29 patients received tocilizumab. 93.1% were men, 37.9% were obese, and 34.5% had hypertension. Of the 20 patients who were not on MV when receiving tocilizumab, 11 required non-invasive MV, for an average of five days, and one of them required intubation. A-a gradient, PaO2/FiO2, and inflammation parameters improved significantly. A better lymphocyte count, which improved significantly after tocilizumab use, was significantly associated with less use of MV. Five patients presented positive culture samples after tocilizumab, three being of clinical significance. A lower lymphocyte count was associated with having a positive culture. No other significant adverse events were seen. Conclusion: Our study suggests the utility and shows the safety of tocilizumab use in COVID-19 patients who have respiratory failure and evidence of hyperinflammation. Lymphocyte improvement was a predictor of good response.
has issue date	2020-08-14(xsd:dateTime)
bibo:doi	10.1101/2020.08.12.20173104
has license	medrxiv
sha1sum (hex)	b464fe04effefb5e23c04a928ba6fe63b62e942e
schema:url	https://doi.org/10.1101/2020.08.12.20173104
resource representing a document's title	First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia
resource representing a document's body	covid:b464fe04effefb5e23c04a928ba6fe63b62e942e#body_text
is schema:about of	named entity 'inhibition' named entity 'hospitalized' named entity 'patients' named entity 'SELECTED' named entity 'USE' named entity 'PRESENT' named entity 'COVID' named entity 'interleukin-6' named entity 'Latin American' named entity 'interleukin' named entity 'infectious diseases' named entity 'procalcitonin' named entity 'SD 36' named entity 'hyperinflammation' named entity 'dalteparin' named entity 'covid-19' named entity 'invasive mechanical ventilation' named entity 'urine' named entity 'Mechanical ventilation' named entity 'multivariate analysis' named entity 'Enterobacter cloacae' named entity 'long term' named entity 'troponin' named entity 'Tocilizumab' named entity 'lymphocyte count' named entity 'gas exchange' named entity 'risk factors' named entity 'tocilizumab' named entity 'prednisone' named entity 'ferritin' named entity 'inflammation' named entity 'medical record' named entity 'retrospective cohort study' named entity 'immunomodulatory' named entity 'ferritin' named entity 'immunomodulatory medication' named entity 'infection' named entity 'NLR' named entity 'multivariate analysis' named entity 'transaminases' named entity 'retroperitoneal' named entity 'COVID-19' named entity 'T-cell' named entity 'infusion' named entity 'multivariate analysis' named entity 'prostate cancer' named entity 'tocilizumab' named entity 'Latin American' named entity 'risks and benefits' named entity 'statistically significant' named entity 'tocilizumab' named entity 'rheumatology' named entity 'intensive care medicine' named entity 'tocilizumab' named entity 'ng/mL' named entity 'tocilizumab' named entity '60 minutes' named entity 'immunosuppressive agent' named entity 'lytic' named entity 'stage II' named entity 'interquartile range' named entity 'prophylactic' named entity 'partial pressure' named entity 'tocilizumab' named entity 'observational study' named entity 'computed axial tomography' named entity 'tocilizumab' named entity 'fungi' named entity 'methicillin-sensitive Staphylococcus aureus' named entity 'intubation' named entity 'lymphopenia' named entity 'tocilizumab' named entity 'infusion' named entity 'ng/mL' named entity 'lymphocytes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software